NVO Stock up on Plans to Advance Obesity Candidate Amycretin

Novo Nordisk (NVO) shares rose nearly 3% on June 12 after announcing plans to advance its novel weight management drug, amycretin, into phase III trials, with studies expected to begin in Q1 2026. The decision follows positive feedback from regulatory authorities on both subcutaneous and oral formulations of the GLP-1 and amylin co-agonist. While NVO stock is down 4.7% YTD amid competition from Eli Lilly and previous supply shortages, recent news of Parvus Asset Management building a stake to influence CEO selection has provided some recovery.

Analysis

Novo Nordisk's decision to advance its novel weight management candidate, amycretin, into Phase III development, with trials slated to begin in Q1 2026, prompted a 2.95% rise in its shares on June 12. Amycretin, a dual GLP-1 and amylin receptor co-agonist being developed in both subcutaneous and oral forms, underscores NVO's strategic focus on next-generation obesity treatments following the success of Wegovy and Ozempic. The company further anticipates key readouts shortly, including full Phase III results for CagriSema and an FDA decision on oral semaglutide 25mg for obesity expected around year-end. Despite these pipeline developments, NVO's stock has registered a 4.7% decline year-to-date, underperforming the industry's 2.9% growth, reflecting intense competition, notably from Eli Lilly, and prior operational challenges such as supply constraints, which were resolved in February 2025. Recent positive momentum includes a 5% stock increase on June 10, reportedly driven by activist hedge fund Parvus Asset Management accumulating a stake to influence the selection of a new CEO, following the announced departure of Lars Fruergaard Jørgensen. Novo Nordisk currently holds a Zacks Rank #3 (Hold), while peers such as Novartis and Bayer exhibit stronger recent stock performance and upward EPS estimate revisions.

Key Decisions for Investors

• Investors should acknowledge the long-term growth potential from amycretin's advancement, while factoring in the Q1 2026 Phase III initiation timeline and the highly competitive obesity market dynamics.
• Monitor upcoming catalysts closely, specifically the full Phase III REDEFINE 1 and 2 study results for CagriSema and the FDA's decision on oral semaglutide 25mg by year-end, as these could materially influence near-term stock performance.
• Assess the potential impact of activist investor involvement by Parvus Asset Management and the forthcoming CEO transition on Novo Nordisk's strategic direction and corporate governance.